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The  thermodynamic  behaviour  of  selected  polymeric  components  for preparation  of  controlled  release
microparticles  using  supercritical  carbon  dioxide  (scCO2)  processing  was  investigated.  The  polymeric
materials  selected  were  egg  lecithin  (a model  for the  lung  surfactant  phospholipid),  poly(ethyleneglycol)
(PEG)  of  different  molecular  weights,  fatty acids  (C18,  C16,  and  C14),  and  physical  blends  of PEGs  and  fatty
acids.  In addition  a range  of PEG-stearates  was  also  assessed.  Analysis  of thermodynamic  behaviour  was
performed  by  differential  scanning  calorimetry  (DSC)  and  by assessment  of their interaction  with  scCO2
in a high-pressure  variable  volume  view  cell.  The  key  criterion  was to  demonstrate  a strong  interaction
with  scCO2 and  to show  liquefaction  of the  polymeric  material  at acceptable  processing  temperatures  andEG
GSS
olymer blends
igh  pressure variable volume view cell
pressures.  Positive  results  should  then  indicate  the  suitability  of  these  materials  for  processing  by the  Par-
ticle  from  Gas  Saturated  Solutions  (PGSS)  technique  using  scCO2 to  create  microparticles  for  pulmonary
administration.  It was  found  that  the materials  tested  interacted  with  scCO2 and  showed  a  sufﬁcient
lowering  of  their  melting  temperature  (Tm)  to make  them  suitable  for use in  the  PGSS microparticle  pro-
duction  rig.  Fatty  acids  of  low  Tm were  shown  to  act as  a plasticising  agent  and  to  lower  the  Tm of  PEG
 withfurther  during  interaction
. Introduction
In recent years, there has been an increasing interest in deliv-
ry of peptides and proteins to the systemic circulation using the
ulmonary route. This is due to the relatively high bioavailabil-
ty achievable after application of such drugs to the lungs, mainly
aused by the large surface area of the lungs (140 m2) available for
rug absorption, the large blood supply to the pulmonary region
nd also the presence of a thin alveoli mucous membrane enabling
he rapid transport of even large biological drugs across the epithe-
ial membrane (Patton et al., 2004). Researchers have especially
een interested in the development of microparticulate systems
or the encapsulation of drugs and delivery mainly to the alveoli for
apid or sustained absorption (Patton, 1996; Cryan, 2005). Unfor-
unately, the use of the pulmonary route peptide and protein
elivery via the lungs was negatively impacted by the withdrawal
f Exubera, the ﬁrst pulmonary insulin product (in the form of a
icroparticulate powder formulation), from the market after less
∗ Corresponding author at: IDentity, 19 Cavendish Crescent North, The Park, Not-
ingham NG7 1BA, UK. Tel.: +44 1159481866.
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than one year, because of low patient and physician acceptance
and hence disappointing sales. This resulted in several other phar-
maceutical companies terminating their development efforts on
pulmonary insulin.
Several  defensive and clearance mechanismsz are present in the
lungs, to prevent the entry into the body of unwanted particles
which may  be inert, toxic, carcinogenic, allergenic or infectious
(Gehr and Hyder, 2000). Excessive intake of foreign particles from
sources such as polluted air and cigarette smoke, and the subse-
quent build-up, can cause severe damage and be detrimental to
health (Adjei and Gupta, 1997). Although, drug delivery to the lungs
using various delivery systems, such as microparticles, has a long
history, the toxicology of the materials used for such systems may
not be totally understood. It is therefore important to choose mate-
rials well known and accepted for pharmaceutical formulations,
such as Generally Recognised AS Safe (GRAS) materials or those
already present to some degree in the body, although the biocom-
patibility of such materials in the lungs may  not be known Also,
these materials need to be amenable to the formulation technology
Open access under CC BY license.adopted for production of pulmonary microparticles.
The most common methods used for the encapsulation of drugs
such as peptides and proteins using polymer materials, are based on
emulsiﬁcation and/or solvent evaporation techniques, spray drying
2 Journal of Pharmaceutics 438 (2012) 225– 231
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body and head units are made from stainless steel (316 SS) which
house a sapphire window and a transparent moveable sapphire
piston.26 M. Vijayaraghavan et al. / International 
nd extrusion techniques, or combinations or variations thereof.
owever, most of these methods require either the use of solvents
or dissolution of the polymer or high temperatures and hence are
ot suitable for encapsulation of peptides and proteins, since this
ould result in loss of bioactivity. The use of a supercritical ﬂuid
reparation method such as the Particle from Gas Saturated Solu-
ions (PGSS) technique, for production of microparticles suitable
or lung delivery of biological drugs is an attractive alternative to
onventional methods, since this method allows processing at low
emperature without the involvement of solvents (Upton et al.,
010; Naylor et al., 2011; Jordan et al., 2010). The PGSS process
elies on the ability of scCO2 to plasticize or liquefy the materials
sed for the encapsulation of drugs, by diffusing into the polymer
hains, detangling these and thereby lowering the glass transition
emperature (Tg) and the melting temperature (Tm). The drug par-
icle generally remains in the solid state and can be mixed with
he liqueﬁed polymer material upon which the mixture is solidi-
ed (encapsulating the drug) by spraying through a nozzle into a
ow-pressure environment. The liqueﬁed material must have a low
iscosity (when liqueﬁed) to enable spraying into suitably small
icroparticles in the range of 2–5 m in aerodynamic diameter in
rder to reach the alveoli after pulmonary administration.
Polymers, such as PLGA and PEG, are commonly used mate-
ials for encapsulation of drugs since they are readily available
nd accepted by regulatory authorities for human use (O’Hara
nd Hickey, 2000; Coowanitwong et al., 2008; Upton et al., 2010;
aylor et al., 2011). However, depending on their molecular weight,
hat governs their crystallinity and permeability to biological ﬂu-
ds, PLGA degrades over at least several weeks or months which
ould not be suitable for lung administration because of build
p of material, whereas PEG is better suited with its general sol-
bility in aqueous solutions (Batycky et al., 1997; Stolnik et al.,
995).
The phospholipids present in the pulmonary surfactant layer
n the alveoli could be a suitable material for use in produc-
ion of microparticles. The major function of the surfactant is to
ower the surface tension at the air–water interface of the alveoli,
hich reduces the tendency of the alveoli to collapse at the end
f expiration (Veldhuizen et al., 1998). The pulmonary surfactant
s composed of approximately 90% lipids and 10% protein. Of the
ipids 80% are made up of phosphatidylcholine, with the remaining
0% being cholesterol, triacylglycerol and free fatty acids (Creuwels
t al., 1997). Recently, solid lipid nanoparticles, where the lipid used
aries from fatty acids to phospholipids, have gained interest for
se in drug delivery (Liu et al., 2008; Mezzena et al., 2009).
Fatty  acids comprise a carboxylic acid group and a hydrocarbon
hain of varying length and can be saturated or mono/bis-
nsaturated. Unsaturated fatty acids are usually liquid at room
emperature and are therefore not suitable for a PGSS produc-
ion process. Saturated fatty acids on the other hand, are usually
olid at room temperature and the most common types, stearic and
almitic acids have relatively low melting temperatures of 60–70 ◦C
nd hence are better suited for production of particles using the
GSS method.
The  interaction of various polymers with scCO2 is well studied.
cCO2 is able to dissolve in amorphous polymers such as PMMA  and
VC (Shieh et al., 1996a) and crystalline polymers such as HDPE
Shieh et al., 1996b) and PEG (Weidner et al., 1997) and thereby
educe the Tg and the Tm, respectively. Biodegradable polymers
uch as PLGA and PLA have also been investigated under scCO2
nd a depression in the Tg has been observed (Tai et al., 2010;
aylor et al., 2011). The solubility and the interaction of phospho-
ipids in and with scCO2 have likewise been studied. However, it
s the evaluation of the liquefaction of the lipids in scCO2 that is
mportant in the PGSS process and this property is not well under-
tood (Guclu-Ustundag and Temelli, 2006; Teberikler et al., 2001).Stearic AcidPEG
Fig. 1. Structure of PEG stearate showing the PEG and stearic acid moieties.
The aim of the present work was to investigate the thermody-
namic behaviour of selected pulmonary components such as egg
lecithin (used as a model for the lung surfactant phospholipid)
and fatty acids during interaction with scCO2 and to evaluate their
suitability for use in production of microparticles using the PGSS
technique. Furthermore, the thermodynamic behaviour of free PEG
in combination with fatty acids and PEG-derivatised-fatty acids was
carried out measuring Tm using a high pressure variable volume
view cell (“view cell”) and DSC.
2. Materials and methods
2.1.  Materials
Egg lecithin (90%) was purchased from Fisher Chemical (Leices-
tershire UK). PEG (MWs  1000, 3000, 3400, 4600 and 6000) were
supplied by Fluka (Dorset, UK). Myristic acid, palmitic acid and
stearic acid (grade 1, purity >98.5%) were purchased from Sigma
Aldrich (Dorset, UK). PEG 100 stearate (PEG MW 4400 Da) (Fig. 1),
PEG 40 stearate (PEG MW 1760 Da) and PEG 8 stearate (PEG
MW 352 Da) were provided by Croda (Yorkshire, UK) and PEG 20
stearate (PEG MW 880 Da) by Adina (Kent, UK). CO2 pharmaceutical
grade was supplied by BOC. All reagents were used as received.
2.2.  High pressure variable volume view cell (“view cell”)
The  temperatures and CO2 pressures required to observe phase
changes in egg lecithin, PEG, fatty acids and the blends were
determined using a view cell. The view cell containing optically
transparent sapphire windows was  developed by License et al.
(2004). The system consists of three main units; a view cell, a
moderated hydraulic pressure intensiﬁer/positional ram, and an
integrated, electronic remote control unit (Fig. 2). The view cellFig. 2. High pressure variable volume view cell illustrating its main components.
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fig. 3. Exposure of egg lecithin to scCO2 in view cell: (a) egg lecithin in the form of
The view cell allows the observation of the phase behaviour of
aterials under scCO2. In the present work, the temperature and
ressure at which materials become liquid in scCO2 is of particular
nterest, as it can be applied to the PGSS process. In a typical exper-
ment, the materials (∼2 g) were weighed into the view cell along
ith a magnetic stirrer and the front sapphire window assembled.
O2 was added to the view cell through the inlet valve. The view
ell was heated to 35 ◦C and the pressure was slowly increased
o approximately 140 bar, whilst observing the sample for any
hanges. Once at the required temperature, the pressure was slowly
ncreased to 340 bar. After being held at this pressure for 10 min,
t was reduced to 140 bar. This process was carried out at 35, 45,
5, 65 and 75 ◦C, allowing the sample to equilibrate at each tem-
erature for 1 h. A magnetic stirrer was used within the view cell
o qualitatively assess the viscosity of the materials.
.3. Differential scanning calorimetry (DSC)
The thermal behaviour of the selected samples was  analysed
sing a TA-Q2000 differential scanning calorimeter (TA instru-
ents), calibrated with an indium standard. Typically, the sample
2–5 mg)  was weighed into a Tzero DSC pan. This pan was sealed
ith a Tzero DSC lid using a Tzero press containing a Black Tzero
ower die and a ﬂat die. A temperature range of 0–100 ◦C was
canned using a heating rate of 10 ◦C/min. The melting tempera-
ure of the material was recorded as Tm and each measurement
as performed in triplicate..4.  Statistical methods
Statistical  analyses were performed where possible, using
icrosoft Excel. Analyses were calculated using one-way ANOVA
ig. 4. View cell showing the addition of 0.5 ml  of (a) ethanol and (b) 0.5 ml  of methanol to
or (b).ow solid and (b) under scCO2 at 75 ◦C and 145 bar. No phase change was  observed.
and  any differences in the results were considered signiﬁcant if the
p-value was  less than 0.05.
3.  Results and discussion
3.1.  Egg lecithin
Egg  lecithin was used as a model for the phospholipids
that  are found in lung surfactant, and is a mixture of different
phospholipids such as diacylphosphatidylethanolamines and phos-
phatidylcholine and is 90% pure. The exact composition of the
phospholipids and the nature of the impurities were not known.
When the egg lecithin was exposed to scCO2 at temperatures
up to 75 ◦C and pressures of 345 bar in the high-pressure view
cell no changes or softening of the egg lecithin was  observed
(Fig. 3). The melting temperature of phospholipid is quite high e.g.
diacylphosphatidylethanolamines and phosphatidylcholine have
melting temperatures of about 200 ◦C and 230 ◦C, respectively. It
was not necessary to evaluate processing temperatures above 75 ◦C
since this would be unsuitable for peptide and protein encap-
sulation. Clearly egg lecithin (phospholipids) is not suitable for
processing in a PGSS microparticle production process.
The  low solubility of pure phospholipids in scCO2 has been
observed by other research groups when trying to extract lipidic
products from a natural source (Montanari et al., 1999; Teberikler
et al., 2001; King, 2004). To improve this process, polar co-solvents
have been used to enhance the solubility for extraction and puriﬁ-
cation by supercritical ﬂuid techniques (Teberikler et al., 2001).
Therefore, ethanol and methanol were introduced into the view
cell along with scCO2 to assess the effect upon egg lecithin. As
little as 0.5 ml  ethanol clearly introduced semi-liquefaction of the
0.5 g egg lecithin (Fig. 4). Increasing the amount of ethanol to 1 ml
 egg lecithin in scCO2 at 45 ◦C and approximately 140 bar with complete liquefaction
228 M. Vijayaraghavan et al. / International Journal of Pharmaceutics 438 (2012) 225– 231
Table 1
Tm of fatty acids as measured by DSC and under scCO2 at 140 bar in a view cell.
Fatty acid carbon atoms DSC melting temperature (Tm) (◦C) Melting temperature (Tm) in view cell under scCO2 (◦C)
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Table 2
Tm of different molecular weights PEG as measured by DSC and under scCO2 at
140  bar observed in the view cell.
Material DSC Melting temperature
(Tm) (◦C)
Melting temperature
(Tm) in view cell under
scCO2 (◦C)
PEG 6000 62.7 ±  0.3 44–46
PEG 4600 61.0 ±  0.9 45–48
PEG 3400 59.3 ± 0.6 40–43Stearic acid 18 71.8 ± 0.8 
Palmitic acid 16 62.6 ±  0.7 
Myristic acid 14 54.3 ± 0.3 
r replacing it with 0.5 ml  of methanol led to complete liquefac-
ion. The introduction of the polar solvents changes the polarity
f the scCO2, which meant that an interaction was possible with
gg lecithin. Hence, from these experiments it can be concluded,
hat egg lecithin is only suitable for preparation of particles using
he PGSS method if polar solvents such as ethanol or methanol are
ntroduced into the process.
.2.  Fatty acids
Possible  substitutes for phospholipids are fatty acids, which
orm an important constituent of the phospholipid structure and
re also present in lung surfactant. Fatty acids have previously been
sed to prepare solid lipid nanoparticles (Liu et al., 2008). In the
resent work stearic, palmitic and myristic acids were selected
or investigation, because the former two are commonly found
n nature and since myristic acid has a lower melting temper-
ture. The fatty acid characteristics and melting temperature as
easured by DSC and evaluated in the view cell are shown in
able 1 and Fig. 5. The DSC thermographs show single Tm peaks.
he view cell experiments demonstrated that at 140 bar, a 10–15 ◦C
epression in Tm for the fatty acids, was observed when exposed
o scCO2. The depression in Tm was largest (15 ◦C) for the myris-
ic acid with the shortest fatty acid chain length, which was  most
ikely due to a higher solubility of the scCO2 in the less rigid (less
rystalline) structure of myristic acid as compared to stearic acid
10 ◦C).
When liqueﬁed, all three fatty acids formed clear liquids.
he behaviour of fatty acids has been investigated by several
esearch groups but only in relation to fractionation and extrac-
ion from mixtures of natural products (Guclu-Ustundag and
emelli, 2005; Bamberger et al., 1988; Garlapati and Madras, 2010).
f the fatty acids investigated, myristic acids melted at 40 ◦C
nd 15 MPa  (150 bar) in agreement with the results presented
ere. These authors also noted, that palmitic acid did not melt,
hereas our data demonstrate that a slightly higher temperature is
equired.
Fig. 5. DSC thermographs of myristic, palmitic and sPEG 3000 59.1 ± 0.2 40–42
PEG 1000 37.5 ±  0.4 Below 30
It can be concluded that all three of the fatty acids tested here
showed thermodynamic properties that would be suitable for use
in the PGSS particle production.
3.3. Polyethyleneglycol (PEG)
PEG is a material with suitable characteristics for pharmaceuti-
cal use and for microparticle production using the PGSS method in
particular (Naylor et al., 2011). It is a GRAS material and hence non-
toxic with approval by regulatory authorities for oral and parenteral
pharmaceutical use. At molecular weights below 1000 Da, PEG
exists as a colourless viscous liquid, and above as a white waxy solid.
The Tm is normally proportional to the molecular weight, reaching
a plateau of 67 ◦C. Furthermore, PEG is water soluble enabling it
to be dissolved in body ﬂuids and quickly cleared (Harris, 1992).
A range of PEGs with different molecular weights from 1000 Da to
6000 Da were investigated using DSC (Fig. 6) and in the view cell
under scCO2. The PEGs were not melted and recrystallised before
use to better mimic  the PGSS microparticle production process. The
PEGs melting temperatures as measured by DSC are shown in Fig. 6
and Table 2 and the Tm values as evaluated in the view cell under
scCO2 are shown in Table 2.The different PEGs evaluated in the study all showed single Tm
peaks and as expected the Tm values were found to decrease with
decreasing molecular weight, with a Tm for PEG 6000 of 62.7 ◦C and
of 37.5 ◦C for PEG 1000 (Fig. 6 and Table 2).
tearic acids showing distinct single Tm peaks.
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As observed for the fatty acids, a depression in Tm of all PEG
olymers was observed in the presence of scCO2. Due to the low
tarting Tm of PEG 1000 the polymer was liqueﬁed already at room
emperature, before CO2 reached the critical point. For all other
EG molecular weights, the material remained solid until exposed
o scCO2. As can be seen from Table 2, all Tms were signiﬁcantly
educed.
The reduction in Tm can be attributed to the dissolution of scCO2
n PEG. Applying a pressure to a substance often results in an
ncrease in melting temperature (Greenwald et al., 2003). How-
ver, the effect of hydrostatic pressure is more than overcome by
he absorption of scCO2 into the polymer that swells the matrix and
ncreases the free volume between the chains. Therefore, scCO2 acts
s molecular lubricant, increasing the segmental and chain mobility
nd increasing the inter-chain distance (King, 2004). The gaseous
roperties of scCO2 mean that it is ideal to diffuse between the poly-
er chains. This process is more efﬁcient in amorphous regions of
he polymer than in crystalline regions, since here less hindrance
s found, because of a lack of regular structure and high density of
nteractions (Shieh et al., 1996a,b). Consequently, there is a compe-
ition between the effect of the high pressure and scCO2. Weidner
t al. (1997) showed that up to approximately 10 bar (145 psi) the
iquefaction temperature increased. At a pressure above 10 bar the
m in scCO2 decreases. However, as the pressure increases further,
he effect of scCO2 in reducing the Tm then becomes outweighed by
he hydrostatic pressure, and the temperature of the solid–liquid
ransition begins to increase. For PEG with molecular weights of
500, 4000 and 35,000 this upper limit is between 210 bar and
40 bar (Greenwald et al., 2003). Therefore, when PEG is used in
he PGSS process it is more efﬁcient to work below this pressure.
.4.  PEG-stearatesPEG-stearates are molecules comprised of PEG chemically
onded to stearic acid through an ester linkage, and combine the
unctionalities of both PEG and stearate in the same molecule.
able 3
elting temperature of different PEG stearates as measured by DSC and under scCO2 at a
elting  temperature of 15–20 ◦C was observed on addition of scCO2.
Material Molecular weight of PEG (Da) Meltin
PEG 100 stearate 4400 55.5 ±
PEG 40 stearate 1760 49.1 ±
PEG 20 stearate 880 39.9 ±
PEG 8 stearate 352 28.0 ±4600 and PEG 6000 demonstrating single distinct Tm peaks.
These  chemicals are generally used in the cosmetic industry in
products such as moisturisers and as emulsifying agents and sur-
factants (Teberikler et al., 2001). The different PEG-stearates used
in the experiments are listed in Table 3. The number in the nomen-
clature refers to the number of ethylene glycol units present in
the molecule. It is ﬁrst of all evident that all of the PEG-stearates
have melting temperatures that are lower than both the individual
Tm of stearic acid (71.8 ◦C) and of a similar molecular weight PEG
(Tables 1 and 2). The behaviour of these materials was investigated
in scCO2 and compared to their Tm under atmospheric conditions
(Table 3).
There  are very few examples of PEG-stearates used in drug deliv-
ery and no instances of these materials being evaluated in scCO2
(Teberikler et al., 2001; Clifford, 1999). In scCO2, PEG-stearates
exhibit a depression in Tm and give a clear substance which is eas-
ily stirred, similar to fatty acids and PEG. It is clear that the PEG
stearates can be processed using scCO2 and it is likely that they
would be suitable for the preparation of microparticles using the
PGSS process.
3.5.  Fatty acid and PEG blends
As  discussed above, the PEG-stearates exhibited a lower Tm than
the individual PEG and stearic acid components, and hence it was
investigated whether a physical mixture of PEG and stearic acid in a
similar way would have a lower Tm. It is known that two physically
mixed polymers often behave similarly to their chemically bonded
copolymers (Bamberger et al., 1988). Therefore, a PEG:fatty acid
(1:1, w/w) ratio was used to investigate the effect of a physical
blending on the Tm as measured by DSC and in the view cell under
scCO2.
The  DSC traces for a 1:1 blend of PEG 6000 with the three differ-
ent fatty acids are shown in Fig. 7. In comparison, the DSC traces for
the individual components of PEG 6000 (Tm −62.7 ◦C), stearic acid
(18 carbon atoms, Tm −71.8 ◦C), palmitic acid (16 carbon atoms,
Tm −62.6 ◦C), and myristic acid (14 carbon atoms, Tm −54.3 ◦C) are
pproximately 140 bar as observed in the variable volume view cell. A depression in
g temperature (Tm) (◦C) Melting temperature (Tm) in scCO2 (◦C)
 0.4 39–42
 0.8 30–33
 0.3 Below 30 (liquid CO2)
 0.9 Below 30 (liquid CO2)
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m peaks (stearic acid blend).
hown in Figs. 5 and 6. Each of the materials show a single Tm peak
nd the Tm values of palmitic acid and PEG 6000 are very close.
or both of the blends containing myristic and palmitic acids a sin-
le peak is present between the Tm of the two separate materials
ndicating formation of a blend. Myristic acid interacted with PEG
000 and reduced the Tm of the blend to a value that is close to
hat of myristic acid whereas the PEG 6000:palmitic acid blend
emained around 63 ◦C, similar to the two components. The trace
or the PEG:stearic acid blend shows the presence of two  peaks, not
ntirely separated. This is due to the low Tm of PEG 6000 (62.7 ◦C)
ombined with the high Tm of stearic acid (71.8 ◦C). This broad-
ning of the Tm range and shift towards lower values have been
eported previously and can be explained by PEG/fatty acid act-
ng as an impurity for each other and disrupting the crystalline
tructure (Pielichowski and Flejtuch, 2003).
The blends prepared with PEG 4600, PEG 3400 and PEG 3000
nd the three different fatty acids showed similar results to those
repared with PEG 6000 (Table 4), whereas the blends prepared
ith PEG 1000 showed different thermal behaviour. By contrast,
he DSC traces for 1:1 blends of PEG 1000 clearly show two peaks.
he Tm values of the blends are slightly lower than those of PEG
000 and the individual fatty acids. This suggests that some inter-
ction, such as hydrogen bonding between the fatty acid and PEG
olecules, has occurred which resulted in the disruption of the
rystalline structure and subsequent reduction in Tm.
When the blends were exposed to scCO2, the material with the
owest Tm value was seen to liquefy ﬁrst leaving the other material
olid (data not shown). As the temperature was increased above the
m of the second material, a single clear liquid was formed. There
as no observed reduction in the Tm of the fatty acids in the pres-
nce of PEG. However, when a fatty acid with a temperature lower
han the PEG was used, the Tm of PEG was reduced. One possible
xplanation for this is that the liqueﬁed fatty acid molecules inﬁl-
rate and disrupt the crystalline PEG lattice. As stearic acid liqueﬁes
able 4
m values of PEG:fatty acid blends (1:1) as measured by DSC.
Melting temperatures (Tm) of PEG:fatty acid blends (◦C)
Stearic acid Palmitic acid Myristic acid
PEG 6000 61.6, 69.9 59.9 55.9
PEG 4600 57.9, 69.0 63.3 55.9
PEG 3400 58.6, 69.5 62.9 54.0
PEG 3000 58.2, 68.7 57.9 54.5
PEG 1000 35.4, 68.9 31.7, 61.6 34.9, 52.3ristic acids showing single Tm peaks (palmitic and myristic acid blends) and double
after PEG, it cannot penetrate the lattice and therefore has no effect
on the melting of PEG in scCO2.
4. Conclusion
The thermodynamic behaviour in terms of Tm of selected pul-
monary components such as egg lecithin and fatty acids were
evaluated both by DSC and in a view cell during interaction
with scCO2. On the basis of this data, their suitability for use in
production of microparticles using the PGSS technique based on
supercritical carbon dioxide scCO2, was assessed. The key criterion
is to show that the polymer material (phospholipid or fatty acid)
has sufﬁcient interaction with scCO2 to be liqueﬁed under accessi-
ble pressures and temperatures and to enable the mixing with solid
drug particles to produce microparticles encapsulating the drug,
after venting the scCO2–polymer–drug mixture into a lower pres-
sure chamber. It is important for the production of microparticles
using the PGSS production technique that the viscosity of the lique-
ﬁed polymer(s) is low. The viscosity has in general been shown by
our group to be directly related to the Tm of the polymer or polymer
mixture used.
The  generally high melting temperatures of phospholipids
resulted in the egg lecithin showing no interaction with scCO2
and remaining solid at a temperature of 75 ◦C and high (345 bar)
pressure of scCO2 in the view cell, and hence egg lecithin was not
investigated further. As fatty acids are an important constituent
of phospholipids, three fatty acids, stearic acid, palmitic acid and
myristic acid with the lowest Tm were investigated. A 10–15 ◦C
depression in the Tm was  observed when the fatty acids were
exposed to scCO2. PEG and PEG-stearates were also exposed to
scCO2 with similar results. Furthermore, blends of different molec-
ular weight PEGs and different fatty acids were also exposed to
scCO2 in order to evaluate the effect of a physical blending com-
pared to chemical bonding of the components. The chemically
bonded PEG-stearates generally showed a single Tm peak, whereas
the Tm peaks for the physical blends for all PEG molecular weights
and fatty acids in general showed a double peak with two distin-
guishable Tm values. It was  observed in the physical blends, that
if the fatty acid had a lower melting point than the PEG, it could
act as a plasticising agent and reduce the Tm in scCO2. However
PEG did not have that effect on fatty acids. The materials evaluated
here are solid at room temperature and can be liqueﬁed at rela-
tively low temperatures using scCO2. They are also generally used
in pharmaceuticals and cosmetics suggesting that they might be
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